Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + anlotinib + ET-SPACE hyperthermia
- Development stage
- Unknown
- Lead developer
- Pengyuan Liu
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This multimodal therapeutic regimen combines the immune checkpoint inhibitor tislelizumab, the multi-target receptor tyrosine kinase (RTK) inhibitor anlotinib, and ET-SPACE near-infrared whole-body hyperthermia. Tislelizumab is a humanized IgG4 monoclonal antibody that targets PD-1, preventing its interaction with PD-L1 and PD-L2 to restore anti-tumor immune responses. Anlotinib inhibits multiple RTKs, including VEGFR, FGFR, PDGFR, and c-Kit, exerting anti-angiogenic and anti-proliferative effects. The ET-SPACE device provides whole-body thermal stimulation (reaching rectal temperatures of 38.5–39 °C), which is intended to sensitize the tumor to the pharmacological agents and enhance the overall anti-tumor immune response. This combination is being evaluated in a Phase 2 study led by Pengyuan Liu for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
- Other names
- ET-SPACE Hyperthermia with Tislelizumab and Anlotinib
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on tislelizumab + anlotinib + ET-SPACE hyperthermia.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + anlotinib + ET-SPACE hyperthermia.